|
|
Evaluation of Tumor Necrosis Factor Related Apoptosis Inducing Ligand (TRAIL) as a Response Marker for Interferon beta in Multiple Sclerosis
|
|
Maha
Nada1, Salma H. Khaleel1, Iman M. Bayoumy1,
Rania Ahmed Hassan2
|
|
Departments of
Neurology1, Medical Microbiology & Immunology2,
Ain Shams University; Egypt
|
ABSTRACT
|
Background: Multiple sclerosis is the
most common disease of the CNS that causes long and severe disability in young
adults. Some patients with relapsing-remitting MS (RRMS) are unresponsive to IFN-β
therapy. The Tumor necrosis factor Related Apoptosis Inducing Ligand
(TRAIL) level was proposed as a response marker for IFN beta treatment. Objective:
To recognize patients who will benefit most from treatment by assessing the
functional relevance of TRAIL, to the clinical treatment response. Methods:
This study was done on 24 patients from the Neurology department, Ain Shams
University Hospitals. Patients had relapsing-remitting multiple sclerosis, for
longer than 1 year. Patients were selected with no immunomodulatory treatment,
and no exacerbations 4 weeks before start of study. Patients were
examined clinically. MRI examinations were done before, 6 months and at the end
of treatment. Estimation of TRAIL levels on monocytes and lymphocytes surfaces
was done before treatment. Patients were given 44µg interferon beta 1a by
subcutaneous injection three times per week for 1 year. Responders were defined
as patients with no relapses and non-responders with one or more relapses
during treatment (one year). Results: Responders showed higher values in
the number of lymphocytes and monocytes having TRAIL and in the amount of TRAIL
on them. Clinically worse patients showed higher number of monocytes having
TRAIL. Conclusion: All the markers of TRAIL were increased in the
responder group .The monocyte level was increased in clinically worse patients,
which suggests that monocytes can be a better marker than lymphocytes. [Egypt J Neurol Psychiat
Neurosurg. 2014; 51(2): 201-206]
Key Words: TRAIL,
Multiple Sclerosis, Interferon beta.
Correspondence to Iman Bayoumy, Neurology Department, Ain Shams University, Egypt. Tel.: +201002595522. Email:
imanbayomy@yahoo.com
|
|
|